All In Biotech

Drug Trial Radar · NCT07669519

Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy

Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Aug 18, 2025

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Natureceuticals Sdn BhdIndustry
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate whether Nuvastatic can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: Does Nuvastatic significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic safe and well tolerated in this patient population? Researchers will compare Nuvastatic vs placebo to see if Nuvastatic improves fatigue scores and maintains an acceptable safety profile. Participants will: Receive Nuvastatic or placebo sachets (3 times per day) for 3 cycles of 20 days each (total \~60 treatment days). Continue their standard first-line chemotherapy regimen. Provide blood samples for biomarkers (CEA, CA-125) at Screening and End of Treatment. Complete patient diaries and fatigue assessments as per protocol.

Conditions

  • Fatigue
  • Colon Cancer

Interventions

  • Nuvastatic™Drug

    1000mg Sachet, (1 sachet X 3 times a day)

  • PlaceboDrug

    1000mg sachet, (1 sachet X 3 times a day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in cancer-related fatigue in colon cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo.Time frame: from screening up to 12 weeks
  2. Changes in cancer-related fatigue in colon cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo.Time frame: From Screening up to 12 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Medical Oncology (In Charge - Oncology Unit)

    Srikakulam, Andhra Pradesh, India · Recruiting

  • Hanji Cancer Centre

    Belagavi, Karnataka, India · Recruiting

  • K.R. Hospital, Mysore Medical College & Research Institute

    Mysuru, Karnataka, India · Recruiting

  • Onco- Life Cancer

    Satara, Maharashtra, India · Recruiting

  • Onco-Life Cancer Centre, Pvt. Ltd

    Talegaon Dābhāde, Maharashtra, India · Recruiting

  • Avicenna Hospital

    Lucknow, Uttar Pradesh, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.